Zobrazeno 1 - 7
of 7
pro vyhledávání: '"D S, O'Callaghan"'
Autor:
D. Montani, D. S. O'Callaghan, X. Jaïs, L. Savale, D. Natali, A. Redzepi, S. Hoette, F. Parent, O. Sitbon, G. Simonneau, M. Humbert
Publikováno v:
European Respiratory Review, Vol 18, Iss 114, Pp 272-290 (2009)
Pulmonary hypertension (PH) comprises a heterogeneous group of disorders characterised by increased pulmonary vascular resistance that results in progressive right ventricular failure. In order to translate current evidence into routine clinical prac
Externí odkaz:
https://doaj.org/article/811fbe077c70466990e5c33e872588e9
Publikováno v:
International Journal of Clinical Practice. 61:26-36
Autor:
L, Savale, D S, O'Callaghan, R, Magnier, J, Le Pavec, P, Hervé, X, Jaïs, A, Seferian, M, Humbert, G, Simonneau, O, Sitbon
Publikováno v:
International journal of clinical practice. Supplement. (169)
Portopulmonary hypertension (PoPH) is a rare but life-threatening complication of portal hypertension that is characterised by proliferative changes in the pulmonary microvasculature indistinguishable from other forms of pulmonary arterial hypertensi
Publikováno v:
The Thoracic and cardiovascular surgeon. 56(8)
Primary cardiac angiosarcoma is a rare tumor that may present with features mimicking venous thromboembolic disease, making the diagnosis particularly challenging. Without a high index of suspicion, the majority of cases will remain undetected until
Autor:
D S, O'Callaghan, K, McNeil
Publikováno v:
International journal of clinical practice. Supplement. (160)
At least two thirds of patients with chronic severe left heart disease have associated pulmonary hypertension, and mortality associated with biventricular failure istwo-fold higher compared with isolated left ventricular failure. This review consider
Publikováno v:
International journal of clinical practice. Supplement. (158)
Autor:
D S, O'Callaghan, S P, Gaine
Publikováno v:
International journal of clinical practice. 60(4)
Endothelin (ET-1) is a potent vasoconstrictor and smooth muscle mitogen that mediates its effects through activation of ET-A and ET-B receptors. Pulmonary arterial hypertension (PAH) encompasses a heterogeneous group of disorders characterised by ina